Sunshine Heart Gears Up For Heart Failure Implant Pivotal Trial
This article was originally published in The Gray Sheet
Firm preps for U.S. pivotal trial and European market launch in the third quarter for its minimally invasive, extra-aortic balloon counter-pulsation system for moderate to severe heart failure.
You may also be interested in...
People Briefs: InVivo Therapeutics CEO Resigns; CVPath Institute, Harvard Bioscience Appoint New CEOs
InVivo Therapeutics Holdings Corp. chairman and CEO resigns. CVPath Institute and Harvard Bioscience get new CEOs. Cook Medical appoints VP to lead its aortic intervention clinical division. Sunshine Heart names chief medical officer.
Conmed snaps up Viking Systems. Sunshine Heart’s C-Pulse heart assist device is approved in Europe. KCI patent appeal puts ball back in S&N’s court. More news briefs.
A new Medicare cost-control program aimed at reducing costly hospital readmissions has heart failure squarely in the cross-hairs, and the consequences could mean hundreds of thousands of dollars in lost Medicare revenue for hospitals that fail to meet the new readmission standards. As a result, providers are scrambling to implement programs to assess and reduce heart failure readmissions, and a growing number of device companies are touting a variety of technologies they believe could help them achieve that goal.